Otezla is the brand name for apremilast, a phosphodiesterase 4 (PDE4) inhibitor manufactured by Amgen. Apremilast is FDA-approved for three indications: adult patients with active psoriatic arthritis, adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, and adult patients with oral ulcers associated with Behçet's disease. The standard dosing starts with a 5-day titration from 10mg to 30mg twice daily, then continues at 30mg taken orally twice daily. Amgen also received FDA approval for a pediatric indication in July 2025 for patients 6 years and older with active psoriatic arthritis.
Otezla is dispensed exclusively through specialty pharmacies such as CVS Specialty, Walgreens Specialty, Accredo, and Optum Rx Specialty. It is not available at standard retail pharmacy counters, which limits access for patients without specialty pharmacy benefits. The specialty pharmacy distribution model means that standard GoodRx coupons typically do not apply at these dispensing outlets. The 2026 list price for a 60-tablet (30-day supply) bottle is approximately $5,800, though pharmacy-to-pharmacy variation and any applied benefit can shift that figure considerably. Patients who have Medicare Part D coverage fall under the $2,100 annual out-of-pocket cap established by the Inflation Reduction Act, making Otezla substantially more affordable for Medicare beneficiaries than the retail sticker suggests.
Under the Inflation Reduction Act of 2022, the Centers for Medicare and Medicaid Services selected Otezla for the second cycle of Medicare drug price negotiations. CMS announced the negotiated Maximum Fair Price for Otezla at $1,650 per 30-day supply, a reduction from the pre-negotiation list price of approximately $5,800. That Maximum Fair Price takes effect January 1, 2027, not 2026. For the remainder of 2026, Medicare beneficiaries pay under their plan's formulary tier within the $2,100 annual cap. Starting in 2027, Medicare beneficiaries will pay no more than the $1,650 Maximum Fair Price at any in-network pharmacy, representing a reduction of more than 70 percent from the retail list price. Patients interested in how formulary tier placement affects their 2026 out-of-pocket costs should review the Medicare Part D coverage section below, or use the Medicare Prescription Drug Plan finder at medicare.gov.
What Otezla Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same otezla can cost many times more at a hospital than at your local pharmacy:
2026 Otezla Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Specialty pharmacy (retail, cash, no insurance) | $5,500 - $6,900/month | 2026 list price for 60 tablets (30mg twice daily). Standard GoodRx coupons typically not accepted at specialty pharmacies. |
| Medicare Part D (2026) | $0 - $350/month, capped at $2,100/year | High-priced specialty drug reaches the $2,100 annual cap quickly; many patients pay $0 for the remainder of the year. |
| Commercial insurance (employer or marketplace plan) | $0 - $200/month after prior authorization and co-pay card | Prior authorization and step therapy are standard. The Otezla Co-Pay Card can reduce cost-share to $0 for eligible commercially insured patients. |
| Otezla Co-Pay Card (Amgen SupportPlus) | As little as $0/month for eligible commercially insured patients | Not valid for Medicare, Medicaid, TRICARE, or VA beneficiaries by federal anti-kickback statute. Enroll at otezla.com/enroll. |
| Medicaid | $1 - $4/prescription, with prior authorization | Covered for psoriasis and psoriatic arthritis in most state Medicaid programs with PA. State coverage rules vary. |
Retail prices reflect 2026 specialty pharmacy list-price data. Part D ranges depend on your plan's formulary tier and where you are in your benefit year. The IRA-negotiated Maximum Fair Price of $1,650 takes effect January 1, 2027.
Source: CMS Part D 2026 benefit design, Amgen SupportPlus, CMS IPAY 2027 negotiated prices, specialty pharmacy surveys
Why Hospitals Charge So Much
Otezla is an oral medication taken at home and is rarely administered in an inpatient hospital setting. When a patient is admitted to the hospital while taking Otezla, the hospital may dispense the drug from its own specialty pharmacy at facility rates. Hospital specialty pharmacy charges typically include the drug acquisition cost plus markups for pharmacy handling fees, inventory holding costs, dispensing overhead, and nursing documentation charges. These layers of fees can push an Otezla inpatient charge to $8,500 to $14,000 for a month-equivalent supply, compared to the $5,800 specialty pharmacy list price.
Three structural factors drive the gap between the retail specialty price and the inpatient billed charge. First, hospital formulary contracts often differ from commercial specialty pharmacy contracts, so the acquisition cost is higher. Second, hospitals apply a chargemaster rate to every drug dispensed, which can reflect 200 to 300 percent of acquisition cost. Third, Otezla's classification as a specialty drug triggers additional pharmacy benefit management and oversight charges not present for standard medications. Patients who find Otezla on an itemized inpatient bill at $10,000 or more for a partial-month supply should request a line-item audit and compare the charge to the drug's 2026 wholesale acquisition cost before paying.
Patient Assistance Programs
Amgen, the manufacturer of Otezla, operates several programs to lower out-of-pocket costs. The primary program for commercially insured patients is the Otezla Co-Pay Card, which can reduce monthly cost-share to $0. As of January 1, 2025, the Amgen Safety Net Foundation (ASNF) stopped enrolling new patients. Uninsured or underinsured patients who previously relied on ASNF should now apply to independent co-pay foundations, including the Good Days Foundation, Patient Access Network (PAN) Foundation, HealthWell Foundation, and Patient Advocate Foundation (PAF), all of which fund Otezla-specific grants. Amgen SupportPlus (1-844-468-3952) can help navigate which foundation is currently accepting applications.
Patient assistance programs for Otezla| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Otezla Co-Pay Card (Amgen SupportPlus) | Pay as little as $0/month for commercially insured patients; deductible, coinsurance, and co-pay covered | otezla.com/enroll |
| Good Days Foundation (independent co-pay assistance) | Income-based grants covering co-pays, deductibles, and insurance premiums for eligible patients with psoriasis or psoriatic arthritis | mygooddays.org |
| Patient Access Network (PAN) Foundation | Co-pay assistance grants for underinsured patients; income thresholds vary by disease fund; psoriasis and psoriatic arthritis funds are available | panfoundation.org |
| HealthWell Foundation | Grants for co-pay assistance for plaque psoriasis patients on Otezla; income-based eligibility | healthwellfoundation.org |
| NeedyMeds Drug Discount Card | Variable discount at participating pharmacies; less effective for specialty pharmacy distribution channels | needymeds.org |
Manufacturer savings cards and co-pay cards are not available to Medicare, Medicaid, TRICARE, or VA beneficiaries by federal anti-kickback statute (42 U.S.C. Section 1320a-7b). If you have government insurance, the Otezla Co-Pay Card is blocked by law. Medicare beneficiaries should explore the Part D Extra Help (Low Income Subsidy) program or apply to an independent foundation such as PAN or HealthWell, both of which can accept Medicare patients. For guidance, call Amgen SupportPlus at 1-844-468-3952.
Source: Amgen SupportPlus (otezla.com), Good Days Foundation, PAN Foundation, HealthWell Foundation, NeedyMeds.org
Medicare Part D
Otezla is a Medicare Part D drug. For 2026, all Part D plans are required to cover drugs in the specialty tier, and Otezla qualifies as a specialty-tier medication. Your total annual out-of-pocket cost for all Part D drugs combined is capped at $2,100 under the Inflation Reduction Act of 2022. Given Otezla's high list price of approximately $5,800 per month, many Medicare beneficiaries will reach the $2,100 annual cap within the first month or two of the plan year. Once you reach the cap, you pay $0 for all covered Part D drugs for the remainder of the calendar year.
Medicare Part D formulary tier placement determines your cost-share before you hit the $2,100 cap. Otezla is placed on the specialty tier (Tier 5 in most plans), which carries the highest cost-sharing percentage, typically 25 to 33 percent of the drug's negotiated price. On a specialty drug priced at $5,800 per month, that means your monthly cost-share before hitting the cap could be $1,450 to $1,914. Most Part D plans have a deductible of up to $615 in 2026 that applies first. Patients who anticipate high specialty drug spending should enroll in Part D Extra Help (Low Income Subsidy) if eligible, which can reduce both the deductible and the cost-sharing percentage substantially.
Starting January 1, 2027, Medicare beneficiaries taking Otezla will pay no more than the $1,650 Maximum Fair Price negotiated under the Inflation Reduction Act. That price represents a reduction of more than 70 percent from the 2026 list price and takes effect for all Medicare Part D plans under the Round 2 drug price negotiation program. Until that date, Medicare beneficiaries in 2026 are protected by the $2,100 annual cap. Patients with commercial insurance or Medicaid are not directly affected by the Maximum Fair Price, which applies only to Medicare Part D beneficiaries. For the most current Part D plan options, visit medicare.gov or call 1-800-MEDICARE.
Common Otezla Billing Errors
Otezla is a specialty drug dispensed through a limited specialty pharmacy network. Billing errors are common because the dispensing channel, prior authorization requirements, and formulary tier rules are more complex than for standard retail drugs. If your bill appears higher than expected, check for these issues before paying:
- Prior authorization not submitted or incorrectly denied: Commercial plans and Medicare Part D plans require PA for specialty drugs. If your prescriber did not submit a PA, you may be paying the full specialty cash price unnecessarily. Request your plan's PA form from your prescriber's office.
- Charged at retail pharmacy rate instead of specialty pharmacy benefit: Otezla is not covered under a standard retail pharmacy benefit. It must go through the specialty pharmacy benefit channel. If your plan processes Otezla as a standard retail fill, the claim may be denied or priced incorrectly.
- Otezla Co-Pay Card not applied even though you are commercially insured and enrolled: Ask your specialty pharmacy to confirm the co-pay card BIN/PCN is loaded before each fill. The digital card must be presented to the specialty pharmacy at each fill.
- Medicare Part D deductible charged after you already hit the $2,100 annual out-of-pocket cap: Once you reach $2,100 in calendar-year Part D out-of-pocket spending, you pay $0. If you are charged a deductible or cost-share after that point, call your Part D plan to dispute the charge.
- Step-therapy denial coded as a coverage denial: If your plan requires you to try methotrexate or another conventional DMARD before Otezla, a step-therapy failure has different appeal rights than a pure formulary exclusion. Confirm the denial code before filing your appeal.
Frequently Asked Questions
Is there a generic for Otezla in 2026?
No. No FDA-approved generic apremilast is available in the United States as of 2026. Although the FDA approved generic applications from Alkem Laboratories and others, a U.S. Court of Appeals ruling in 2023 blocked generic market entry until Amgen's primary patent (7,427,638) expires in August 2028. Two additional patents extend through 2034. Generic apremilast is available in Canada and the European Union but not in the US market. Patients facing cost barriers in 2026 should explore the Otezla Co-Pay Card, independent foundations, or the 2027 Medicare Maximum Fair Price if they are Medicare-eligible.
How do I apply for the Otezla patient assistance program?
The Amgen Safety Net Foundation (ASNF) stopped enrolling new patients as of January 1, 2025. For commercially insured patients, enroll in the Otezla Co-Pay Card at otezla.com/enroll or call Amgen SupportPlus at 1-844-468-3952 to pay as little as $0 per month. Uninsured or underinsured patients should call the same number to be connected with an independent foundation (Good Days, PAN Foundation, HealthWell Foundation, or Patient Advocate Foundation) that funds Otezla cost-sharing. Gather your income documentation, proof of US residency, a valid prescription, and your insurance card or denial letter before applying. Processing typically takes 2 to 4 weeks.
Can I use the Otezla Co-Pay Card with Medicare?
No. Federal anti-kickback law (42 U.S.C. Section 1320a-7b) bars manufacturer co-pay cards and manufacturer coupon programs from being used by anyone on Medicare, Medicaid, TRICARE, or VA benefits. The Otezla Co-Pay Card is exclusively for commercially insured patients. Medicare beneficiaries have two main options: apply for Part D Extra Help (Low Income Subsidy) through Social Security to reduce your specialty drug cost-share, or apply to an independent foundation (PAN Foundation or HealthWell Foundation) that can accept Medicare patients. Call Amgen SupportPlus at 1-844-468-3952 for guidance on which program is currently available.
Does the IRA negotiated price apply to Otezla in 2026?
Not yet in 2026. Otezla was selected for the second round of IRA Medicare drug price negotiations (IPAY 2027), and CMS announced a Maximum Fair Price of $1,650 for a 30-day supply. That Maximum Fair Price takes effect January 1, 2027, not January 2026. For the remainder of 2026, Medicare Part D beneficiaries pay under their plan's formulary tier within the $2,100 annual out-of-pocket cap established by the Inflation Reduction Act. Starting January 1, 2027, all Medicare Part D plans must honor the $1,650 Maximum Fair Price, representing a reduction of more than 70 percent from the 2026 retail list price.
What does Otezla cost without insurance at the pharmacy counter in 2026?
Otezla is a specialty drug and is not available at standard retail pharmacy counters. The 2026 retail list price at specialty pharmacies such as CVS Specialty and Walgreens Specialty is approximately $5,500 to $6,900 per 30-day supply (60 tablets at 30mg twice daily). GoodRx lists a coupon price near $3,353, but most specialty pharmacies do not accept third-party discount coupons. Uninsured patients who cannot afford the specialty list price should contact Amgen SupportPlus at 1-844-468-3952 to be connected with an independent patient assistance foundation.
What if my insurance denies coverage for Otezla?
Start by requesting the written denial letter, which must state the specific reason for denial and your appeal rights. File a formal internal appeal within 60 days with clinical documentation of your diagnosis (ICD-10 L40.0 for plaque psoriasis or L40.5 for psoriatic arthritis) and the medical necessity for Otezla. Ask your dermatologist or rheumatologist to request a peer-to-peer review with the plan's medical director. If denied again, escalate to an external independent review through your state Department of Insurance. If appeals fail, apply for co-pay assistance through the Good Days Foundation, PAN Foundation, or HealthWell Foundation while you continue the appeal process. A formulary tier appeal is different from a step-therapy override; confirm which type of denial you received before filing.
Do I qualify for the Otezla patient assistance program?
Eligibility depends on your insurance status and income. For the Otezla Co-Pay Card (commercially insured patients): no income requirement, but you must have active commercial insurance. For independent foundations (uninsured, underinsured, or Medicare patients): income thresholds vary by foundation and by which disease fund is currently open. Generally, annual household income at or below 300 to 500 percent of the federal poverty level ($47,880 to $79,800 for a single person in 2026) is required. You must also be a US resident and have a valid Otezla prescription from a US-licensed prescriber. Call Amgen SupportPlus at 1-844-468-3952 or visit panfoundation.org, mygooddays.org, or healthwellfoundation.org to check current eligibility.
How is Otezla different from biologics like Humira or Cosentyx for psoriasis?
Otezla (apremilast) is an oral small-molecule PDE4 inhibitor, not a biologic. Biologics such as Humira (adalimumab), Cosentyx (secukinumab), or Taltz (ixekizumab) are injectable or infused large-molecule proteins that target specific immune pathways. Otezla's oral route is convenient and avoids injection, but its clinical response rates are generally lower than for newer biologics, especially for moderate-to-severe plaque psoriasis. Otezla does not require baseline tuberculosis screening or routine blood monitoring that some biologics require. Discuss the clinical trade-offs with your dermatologist or rheumatologist. From a cost perspective, Otezla and most biologics fall into the specialty drug tier under both Medicare Part D and commercial plans, though biosimilars for adalimumab (Humira) have driven that drug's price down substantially since 2023.
